LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with ...
LYON, France, October 23, 2025--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic ...
Non-adoption of key financial delegations at the Combined General Meeting held on February 11, 2025 resulted in an adverse and uncertain situation regarding the continuation of the Company’s ...
the 2024 Annual Financial Report, including the Management Report, the Report on Corporate Governance, and the Corporate Social Responsibility (CSR) Report. Printed copies of the Universal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results